7-OH is being banned: what to do if you use it

Status as of August 14, 2026: not yet. The August 5 date passed with nothing filed.

August 5 was the earliest date the DEA could issue its temporary scheduling order. That date has passed and no order has appeared in the Federal Register, so concentrated 7-OH is not federally scheduled today. It can arrive on any day with no warning.

Here is the part that matters more than the legal timeline. Supply has already started changing. Vendors began cutting prices and clearing inventory in July ahead of a ban they expected in early August. Some stores stopped restocking. Whether or not the order ever publishes, availability is becoming unpredictable.

Several states have also acted on their own, including a Massachusetts emergency order on August 13. Those restrictions apply now.

If you have been using concentrated 7-OH products and you are reading this, you are in a window. The question is what to do with it.

Current status at a glance (updated August 14, 2026)

What the DEA actually announced

On July 1, 2026, the Drug Enforcement Administration announced its intent to temporarily place concentrated 7-OH in Schedule I of the Controlled Substances Act. Two notices were filed and published in the Federal Register on July 6, 2026 (Docket DEA-1570 and a related docket):

Notice 1: 7-OH above a specified threshold. Covers 7-hydroxymitragynine at more than 0.05% by dry weight in botanical material, or more than 0.05% by concentration or more than 1.00 milligram per article in synthetic or processed products. Virtually all commercial 7-OH tablets, gummies, and shots fall above this threshold.

Notice 2: Three synthetic derivatives. Covers mitragynine pseudoindoxyl (MP), MGM-15, and MGM-16 at any concentration. None of these compounds occur naturally in the kratom plant.

What is not covered: The DEA and HHS were explicit in their joint statement that this action does not target botanical kratom products containing naturally occurring 7-OH below the specified threshold. Natural leaf kratom is not the subject of this federal scheduling action, though some states go further.

Timeline:

Why the wait. The 30-day period after the notices published is a minimum, not a deadline. Nothing obliges the DEA to act at the end of it, or at all. The agency withdrew a kratom scheduling proposal in 2016 after public and congressional objection. For more on where the federal action stands, see The 2026 7-OH Legal Landscape.

The debate: Advocacy groups representing 7-OH product manufacturers have signaled legal challenges and objected to the use of emergency scheduling authority. The American Kratom Association, which represents botanical kratom consumers, supported the action because it draws a clear line between natural leaf and concentrated synthetic products, though it has since raised concerns that the second notice may reach an alkaloid that occurs naturally in the plant. The leaf and extract distinction is the core of both the regulatory action and the disagreement around it.

Why concentrated 7-OH is so habit-forming

This is worth explaining because a lot of people who use it did not know what they were walking into.

The DEA's notice describes 7-OH as sharing a pharmacological profile with Schedule II opioids, with abuse potential, tolerance, dependence, and respiratory depression comparable to classical opioids. The FDA's 2025 scientific assessment documented this in detail.

What made it feel different from a drug was the delivery mechanism: sold at a gas station, labeled as a supplement, described with wellness language. The product was legal, available over the counter, and presented as botanical. That framing was marketing, not pharmacology.

Concentrated 7-OH activates mu-opioid receptors at potency levels far above what the natural kratom leaf produces. Unlike kratom leaf, which has a ceiling effect that limits respiratory depression, concentrated products have no protective ceiling. Dependence can form within days to weeks of regular use. Tolerance builds, doses escalate, and the window between "the amount that works" and "more than last week" closes faster than most people anticipate.

If this caught up to you without feeling like a conscious choice to develop an opioid habit, that is how the product is designed to work. It is not a personal failing.

The supply is ending before the law does

This is the part almost nobody is covering, and it is more urgent than the federal timeline.

Since early July, vendors have been running clearance sales, discounting heavily, and drawing down inventory rather than restocking. They were preparing for a ban in early August. The ban has not arrived, but the inventory decisions were already made.

What that means in practice: your usual product may become hard to find, or disappear entirely, on a schedule set by a distributor rather than by the government. Some people will hit that wall weeks before any order publishes.

Planning around the federal date is planning around the wrong thing. The question is not when the DEA acts. It is what happens the week your source runs out.

What happens when supply disappears

Concentrated 7-OH withdrawal comes on fast. For most people, symptoms begin within 4 to 6 hours of the last dose. The peak arrives within 2 to 4 days and can be severe, with muscle aches, sweating, anxiety, insomnia, stomach and bowel distress, and intense cravings.

When products leave shelves abruptly, people who have been dosing daily face that withdrawal on a timeline set by someone else rather than a clinical plan. That is the scenario worth avoiding.

Four responses that make it worse

Stockpiling. It is the natural first thought. It does not help. Stockpiling deepens the dependence you will eventually have to address, raises overdose risk as product quality and batch potency continue to vary, and simply delays the same day by a few weeks, usually at a higher daily amount than you are using now. Planning treatment is the productive version of the same impulse.

Panic-quitting cold turkey. Stopping abruptly from significant 7-OH dependence produces full-intensity withdrawal, the hardest and most relapse-prone version of stopping. For most people with daily concentrated 7-OH use, unsupported cold turkey is poorly matched to the pharmacology. See Kratom Withdrawal Timeline for what that looks like.

Switching to kratom leaf. This feels like a step down, but it maintains the same opioid receptor dependence in a milder form. It is not a taper, it is a lateral move. The same withdrawal eventually arrives when the leaf is stopped. See Can You Switch from 7-OH Back to Kratom Powder? for the full explanation.

Switching to street opioids. This is the one that kills people, and it deserves to be said plainly rather than implied.

If you have been taking a labeled product with a consistent amount in every tablet, you have no way to gauge an illicit supply. The current street supply is dominated by fentanyl, which is far more potent and is distributed unevenly within a batch. Tolerance built on concentrated 7-OH does not translate into safety against fentanyl.

This is the specific path that turns a regulatory action into an overdose death, and it is the reason this page exists. If you are anywhere near this decision, that is the moment to call a provider instead. If you do use, do not use alone, and keep naloxone on hand. Naloxone is available over the counter without a prescription and it works on 7-OH and fentanyl alike.

The ban is not the enemy. Being unprepared for it is.

What you can do in the next few weeks

The window between now and when supply ends is the most useful period to act. Here is why:

Starting treatment before supply runs out means:

• The transition is supervised, not forced
• Withdrawal symptoms are largely prevented rather than endured
• You are not making critical clinical decisions in the middle of acute withdrawal

What treatment looks like: Buprenorphine/naloxone (Suboxone) is the evidence-based treatment for 7-OH and kratom dependence. It works by stabilizing the same mu-opioid receptors that 7-OH activates, which is why it prevents withdrawal and cravings. A 2026 clinical guidance paper in Annals of Internal Medicine recommends buprenorphine as the preferred treatment for 7-OH dependence.

How to access it: Telehealth buprenorphine is available in most U.S. states without an in-person visit, often the same day you reach out. You do not have to step away from work, disclose anything to your employer, or navigate a clinic. See Can You Get Suboxone for Kratom Addiction Online? for the current rules and what the process looks like.

If you are thinking "I only use 7-OH, I probably don't qualify": You do. People whose only substance is concentrated kratom or 7-OH are treated with buprenorphine. The pharmacology qualifies you, and the clinical evaluation confirms it. See "I Only Use Kratom": Why That Still Qualifies for MAT.

If you are not sure whether you need help: Ask yourself whether skipping your usual dose feels optional or genuinely difficult. If the answer is the latter, that is physical dependence, and treatment is what addresses it.

What to tell a clinician

When you reach out for a telehealth evaluation, honest information helps the provider make the right clinical plan:

• What product you have been using and roughly how much
• How long you have been using it
• When you last used
• Whether you have tried to stop before and what happened
• Any other medications or substances you use

That is all they need. The evaluation is a clinical conversation, not a test. See Bicycle Health's treatment page for how the process works.

Frequently Asked Questions

Is 7-OH already illegal?

As of August 14, 2026, not federally. The DEA published notices of intent on July 6, 2026, which made August 5 the earliest date the temporary order could issue. That date passed and nothing has been filed. Several states have their own bans in effect, including Massachusetts as of August 13, plus Tennessee, Kansas, Florida, and others. For state-by-state status, see The 2026 7-OH Legal Landscape.

Why has the ban not happened yet?

August 5 was the earliest date the DEA could act, not a deadline. The law requires a 30-day wait after the notices publish; it does not require the agency to act when that period ends. Temporary scheduling orders often arrive weeks or months later, and the DEA withdrew a kratom scheduling proposal in 2016. The order can still publish on any day without warning.

Will kratom leaf products be banned too?

Not under the federal action. The DEA and HHS were explicit that this targets concentrated and synthetic 7-OH above a specified threshold, and that natural kratom leaf containing trace 7-OH below 0.05% by dry weight is not covered. Some states ban all kratom including the leaf under their own laws. Massachusetts issued an emergency order covering all kratom products on August 13, 2026.

My store already stopped carrying it. Is it banned?

Probably not. It is more likely a supply decision. Vendors and retailers began clearing inventory in July ahead of a ban they expected in early August, and many stopped restocking. That means products can become unavailable well before any legal change. If your supply is ending, the practical situation is the same regardless of what the law says.

Can I just stockpile 7-OH before the ban?

This is understandable as an impulse but not a helpful plan. Stockpiling deepens physical dependence, raises overdose risk given variable product potency, and delays addressing the underlying issue, usually at a higher daily amount by the time you run out. If losing access to 7-OH is frightening, that is the situation treatment is designed to help with.

What if I am in withdrawal already?

If you are currently experiencing 7-OH withdrawal and need help today, contact a clinician or call SAMHSA's free helpline at 1-800-662-4357. Buprenorphine can be prescribed via telehealth in most states and can be started once moderate withdrawal has begun. See Get emergency access to buprenorphine.

You do not have to wait for the shelves to clear

Getting treatment before your supply ends means a planned transition rather than a forced one. Telehealth evaluations are available the same day in most states.

If you are in withdrawal now, call SAMHSA's free helpline at 1-800-662-4357 (24/7, confidential) or contact a clinician. If this is a medical emergency, call 911. This article is for general information only. It is not legal advice or medical advice. Regulatory status is subject to change; verify current status before making decisions.

Next Steps

• How Bicycle Health's telehealth treatment works
• Can you get Suboxone for 7-OH online?
• Get emergency access to buprenorphine
• Check your state
• Insurance and pricing information

This article is for educational purposes only and is not a substitute for professional medical advice. If you are experiencing severe withdrawal symptoms, contact a healthcare provider or go to your nearest emergency room.